Global Natural Killer (Nk) Cell Therapeutics Market - Industry Trends And Forecast To 2029
Description
Global Natural Killer (Nk) Cell Therapeutics Market - Industry Trends And Forecast To 2029
Global natural killer (NK) cell therapeutics market is projected to register a CAGR of 40.9% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029
Market Segmentation
Global Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others), Country (U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, Rest of Europe, Japan, China, Australia, South Korea, India, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and rest of Middle East and Africa) – Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the global natural killer (NK) cell therapeutics market are:
• Increase in usage of natural killer (NK) cells for the treatment of cancer and infectious diseases
• Rise in awareness about immunotherapies
• Adoption of natural killer (NK) cell therapy in emerging markets
Market Players
The key market players for global natural killer (NK) cell therapeutics market are listed below:
• Merck KGaA
• Bristol-Myers Squibb Company
• Glycostem
• Kiadis Pharma
• Cytovia Therapeutics
• Nkarta, Inc.
• Nektar
• ImmunityBio, Inc.
• Brink Biologics, Inc.
• Biohaven Pharmaceuticals
• Fate Therapeutics
• EMERcell
• Phio Pharmaceuticals
• PersonGen BioTherapeutics
• Innate Pharma, Inc.
• INmuneBIO
• Gamida Cell
• Acepodia Inc.
• Affimed GmbH
• Multimmune GmbH
• iCell Gene Therapeutics
• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals Inc.
Company Profiles
• Merck KGaA
• Bristol-Myers Squibb Company
• Glycostem
• Kiadis Pharma
• Cytovia Therapeutics
• Nkarta, Inc.
• Nektar
• ImmunityBio, Inc.
• Brink Biologics, Inc.
• Biohaven Pharmaceuticals
• Fate Therapeutics
• EMERcell
• Phio Pharmaceuticals
• PersonGen BioTherapeutics
• Innate Pharma, Inc.
• INmuneBIO
• Gamida Cell
• Acepodia Inc.
• Affimed GmbH
• Multimmune GmbH
• iCell Gene Therapeutics
• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals Inc.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.
Global natural killer (NK) cell therapeutics market is projected to register a CAGR of 40.9% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029
Market Segmentation
Global Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others), Country (U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, Rest of Europe, Japan, China, Australia, South Korea, India, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and rest of Middle East and Africa) – Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the global natural killer (NK) cell therapeutics market are:
• Increase in usage of natural killer (NK) cells for the treatment of cancer and infectious diseases
• Rise in awareness about immunotherapies
• Adoption of natural killer (NK) cell therapy in emerging markets
Market Players
The key market players for global natural killer (NK) cell therapeutics market are listed below:
• Merck KGaA
• Bristol-Myers Squibb Company
• Glycostem
• Kiadis Pharma
• Cytovia Therapeutics
• Nkarta, Inc.
• Nektar
• ImmunityBio, Inc.
• Brink Biologics, Inc.
• Biohaven Pharmaceuticals
• Fate Therapeutics
• EMERcell
• Phio Pharmaceuticals
• PersonGen BioTherapeutics
• Innate Pharma, Inc.
• INmuneBIO
• Gamida Cell
• Acepodia Inc.
• Affimed GmbH
• Multimmune GmbH
• iCell Gene Therapeutics
• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals Inc.
Company Profiles
• Merck KGaA
• Bristol-Myers Squibb Company
• Glycostem
• Kiadis Pharma
• Cytovia Therapeutics
• Nkarta, Inc.
• Nektar
• ImmunityBio, Inc.
• Brink Biologics, Inc.
• Biohaven Pharmaceuticals
• Fate Therapeutics
• EMERcell
• Phio Pharmaceuticals
• PersonGen BioTherapeutics
• Innate Pharma, Inc.
• INmuneBIO
• Gamida Cell
• Acepodia Inc.
• Affimed GmbH
• Multimmune GmbH
• iCell Gene Therapeutics
• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals Inc.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.
Table of Contents
286 Pages
- 1 Introduction
- 1.1 Objectives Of The Study
- 1.2 Market Definition
- 1.3 Overview Of Global Natural Killer (Nk) Cell Therapeutics Market
- 1.4 Limitations
- 1.5 Markets Covered
- 2 Market Segmentation
- 2.1 Markets Covered
- 2.2 Geographical Scope
- 2.3 Years Considered For The Study
- 2.4 Currency And Pricing
- 2.5 Dbmr Tripod Data Validation Model
- 2.6 Multivariate Modelling
- 2.7 Therapeutics Lifeline Curve
- 2.8 Primary Interviews With Key Opinion Leaders
- 2.9 Dbmr Market Position Grid
- 2.10 Secondary Sources
- 2.11 Assumptions
- 3 Executive Summary
- 3.1 Epidemiology
- 3.2 Pestel Analysis
- 3.3 Porter’s Five Forces Model
- 3.4 Industrial Insights:
- 3.5 Pipeline Analysis
- 4 Global Natural Killer (Nk) Cell Therapeutics Market: Regulations
- 5 Market Overview
- 5.1 Drivers
- 5.1.1 Increase In Usage Of Natural Killer (Nk) Cells For The Treatment Of Cancer And Infectious Diseases
- 5.1.2 Increase In Patient Population With Chronic Diseases
- 5.1.3 Rise In Awareness About Immunotherapies
- 5.1.4 Adoption Of Natural Killer (Nk) Cell Therapy In Emerging Markets
- 5.2 Restraints
- 5.2.1 Lack Of Specificity And Poor In-vivo Survival Of The Cells
- 5.2.2 Adverse Side Effects Of Therapies
- 5.2.3 High Cost Associated With The Therapies
- 5.3 Opportunities
- 5.3.1 Advancement In Natural Killer (Nk) Cell Therapies
- 5.3.2 Strategic Initiatives By Market Players
- 5.3.3 Rise In Expenditure In Healthcare Sector
- 5.4 Challenges
- 5.4.1 Long Approval Time For Immunotherapies
- 5.4.2 Lack Of Specific Treatment By Natural Killer (Nk) Cells
- 5.4.3 Availability Of Alternatives For Tumor Treatment
- 6 Global Natural Killer (Nk) Cell Therapeutics Market, By Therapeutics
- 6.1 Overview
- 6.2 Nk Cell Therapies
- 6.3 Nk Cell Directed Antibodies
- 7 Global Natural Killer (Nk) Cell Therapeutics Market, By Approaches
- 7.1 Overview
- 7.2 Antibody-dependent Cell-mediated Cytotoxicity (Adcc)
- 7.3 Bispecific Antibodies
- 8 Global Natural Killer (Nk) Cell Therapeutics Market, By Application
- 8.1 Overview
- 8.2 Cancer
- 8.2.1 Solid Tumors
- 8.2.2 Hematologic Malignancies
- 8.2.2.1 Multiple Myeloma
- 8.2.2.2 Acute Myeloid Leukemia (Aml)
- 8.2.2.3 Lymphoma
- 8.2.2.4 Others
- 8.2.3 Others
- 8.3 Immunoproliferative Disorders
- 8.4 Acute Infectious Diseases
- 8.5 Gastrointestinal Diseases
- 8.6 Others
- 9 Global Natural Killer (Nk) Cell Therapeutics Market, By End User
- 9.1 Overview
- 9.2 Hospitals
- 9.3 Specialty Clinics
- 9.4 Research & Academic Institutes
- 10 Global Natural Killer (Nk) Cell Therapeutics Market, By Distribution Channel
- 10.1 Overview
- 10.2 Hospital Pharmacies
- 10.3 Direct Tender
- 10.4 Others
- 11 Global Natural Killer (Nk) Cell Therapeutics Market, By Region
- 11.1 Overview
- 11.2 North America
- 11.2.1 U.S.
- 11.2.2 Canada
- 11.2.3 Mexico
- 11.3 Europe
- 11.3.1 Germany
- 11.3.2 France
- 11.3.3 Italy
- 11.3.4 U.K.
- 11.3.5 Spain
- 11.3.6 Netherlands
- 11.3.7 Russia
- 11.3.8 Switzerland
- 11.3.9 Turkey
- 11.3.10 Austria
- 11.3.11 Norway
- 11.3.12 Hungary
- 11.3.13 Lithuania
- 11.3.14 Ireland
- 11.3.15 Poland
- 11.3.16 Luxembourg
- 11.3.17 Rest Of Europe
- 11.4 Asia-pacific
- 11.4.1 Japan
- 11.4.2 China
- 11.4.3 Australia
- 11.4.4 South Korea
- 11.4.5 India
- 11.4.6 Singapore
- 11.4.7 Malaysia
- 11.4.8 Thailand
- 11.4.9 Indonesia
- 11.4.10 Philippines
- 11.4.11 Vietnam
- 11.4.12 Rest Of Asia-pacific
- 11.5 South America
- 11.5.1 Brazil
- 11.5.2 Argentina
- 11.5.3 Peru
- 11.5.4 Rest Of South America
- 11.6 Middle East & Africa
- 11.6.1 Saudi Arabia
- 11.6.2 South Africa
- 11.6.3 U.A.E
- 11.6.4 Israel
- 11.6.5 Kuwait
- 11.6.6 Egypt
- 11.6.7 Rest Of Middle East & Africa
- 12 Global Natural Killer (Nk) Cells Therapeutics Market, Company Landscape
- 12.1 Company Share Analysis: Global
- 13 Swot Analysis
- 14 Company Profile
- 14.1 Merck Kgaa
- 14.1.1 Company Snapshot
- 14.1.2 Recent Financials
- 14.1.3 Product Portfolio
- 14.1.4 Recent Developments
- 14.2 Bristol-myers Squibb Company
- 14.2.1 Company Snapshot
- 14.2.2 Recent Financials
- 14.2.3 Product Portfolio
- 14.2.4 Recent Developments
- 14.3 Glycostem
- 14.3.1 Company Snapshot
- 14.3.2 Product Portfolio
- 14.3.3 Recent Developments
- 14.4 Innate Pharma, Inc.
- 14.4.1 Company Snapshot
- 14.4.2 Revenue Analysis
- 14.4.3 Product Portfolio
- 14.4.4 Recent Developments
- 14.5 Regeneron Pharmaceuticals Inc.
- 14.5.1 Company Snapshot
- 14.5.2 Recent Financials
- 14.5.3 Product Portfolio
- 14.5.4 Recent Developments
- 14.6 Takeda Pharmaceutical Company Limited
- 14.6.1 Company Snapshot
- 14.6.2 Recent Financials
- 14.6.3 Product Portfolio
- 14.6.4 Recent Developments
- 14.7 Inmunebio
- 14.7.1 Company Snapshot
- 14.7.2 Revenue Analysis
- 14.7.3 Product Portfolio
- 14.7.4 Recent Developments
- 14.8 Kiadis Pharma
- 14.8.1 Company Snapshot
- 14.8.2 Revenue Analysis
- 14.8.3 Product Portfolio
- 14.8.4 Recent Developments
- 14.9 Acepodia Inc.
- 14.9.1 Company Snapshot
- 14.9.2 Product Portfolio
- 14.9.3 Recent Developments
- 14.10 Affimed Gmbh
- 14.10.1 Company Snapshot
- 14.10.2 Recent Financials
- 14.10.3 Product Portfolio
- 14.10.4 Recent Developments
- 14.11 Biohaven Pharmaceuticals
- 14.11.1 Company Snapshot
- 14.11.2 Revenue Analysis
- 14.11.3 Product Portfolio
- 14.11.4 Recent Developments
- 14.12 Brink Biologics, Inc.
- 14.12.1 Company Snapshot
- 14.12.2 Product Portfolio
- 14.12.3 Recent Development
- 14.13 Cytovia Therapeutics
- 14.13.1 Company Snapshot
- 14.13.2 Product Portfolio
- 14.13.3 Recent Developments
- 14.14 Emercell
- 14.14.1 Company Snapshot
- 14.14.2 Product Portfolio
- 14.14.3 Recent Developments
- 14.15 Fate Therapeutics
- 14.15.1 Company Snapshot
- 14.15.2 Revenue Analysis
- 14.15.3 Product Portfolio
- 14.15.4 Recent Developments
- 14.16 Gamida Cell
- 14.16.1 Company Snapshot
- 14.16.2 Product Portfolio
- 14.16.3 Recent Developments
- 14.17 Icell Gene Therapeutics
- 14.17.1 Company Snapshot
- 14.17.2 Product Portfolio
- 14.17.3 Recent Development
- 14.18 Immunitybio, Inc.
- 14.18.1 Company Snapshot
- 14.18.2 Revenue Analysis
- 14.18.3 Product Portfolio
- 14.18.4 Recent Developments
- 14.19 Multimmune Gmbh
- 14.19.1 Company Snapshot
- 14.19.2 Product Portfolio
- 14.19.3 Recent Developments
- 14.20 Nektar
- 14.20.1 Company Snapshot
- 14.20.2 Revenue Analysis
- 14.20.3 Product Portfolio
- 14.20.4 Recent Developments
- 14.21 Nkarta, Inc.
- 14.21.1 Company Snapshot
- 14.21.2 Product Portfolio
- 14.21.3 Recent Developments
- 14.22 Persongen Biotherapeutics
- 14.22.1 Company Snapshot
- 14.22.2 Product Portfolio
- 14.22.3 Recent Developments
- 14.23 Phio Pharmaceuticals
- 14.23.1 Company Snapshot
- 14.23.2 Product Portfolio
- 14.23.3 Recent Developments
- 15 Questionnaire
- 16 Related Reports
- List Of Figures
- Figure 1 Global Natural Killer (Nk) Cell Therapeutics Market: Segmentation
- Figure 2 Global Natural Killer (Nk) Cell Therapeutics Market : Data Triangulation
- Figure 3 Global Natural Killer (Nk) Cell Therapeutics Market: Droc Analysis
- Figure 4 Global Natural Killer (Nk) Cell Therapeutics Market: Global Vs Regional Market Analysis
- Figure 5 Global Natural Killer (Nk) Cell Therapeutics Market: Company Research Analysis
- Figure 6 Global Natural Killer (Nk) Cell Therapeutics Market: Multivariate Modelling
- Figure 7 Global Natural Killer (Nk) Cell Therapeutics Market: Interview Demographics
- Figure 8 Global Natural Killer (Nk) Cell Therapeutics Market: Dbmr Market Position Grid
- Figure 9 Global Natural Killer (Nk) Cell Therapeutics Market: Vendor Share Analysis
- Figure 10 Global Natural Killer (Nk) Cell Therapeutics Market: Segmentation
- Figure 11 North America Is Expected To Dominate And Asia-pacific Is Growing With The Fastest Pace In The Global Natural Killer (Nk) Cell Therapeutics Market In The Forecast Period Of 2022 To 2029
- Figure 12 Increase In Usage Of Natural Killer Cells For The Treatment Of Cancer And Infectious Diseases And Rise In The Awareness About Immunotherapies Is Driving The Global Natural Killer (Nk) Cell Therapeutics Market In The Forecast Period Of 2022 To 2029
- Figure 13 Nk Cell Therapies Segment Is Expected To Account For The Largest Share Of The Global Natural Killer (Nk) Cell Therapeutics Market In 2022 & 2029
- Figure 14 Asia-pacific Is The Fastest Growing Market For Natural Killer (Nk) Cell Therapeutics Manufacturers In The Forecast Period Of 2022 To 2029
- Figure 15 Drivers, Restraints, Opportunities, And Challenges Of Global Natural Killer (Nk) Cell Therapeutics Market
- Figure 16 Global Natural Killer (Nk) Cell Therapeutics Market: By Therapeutics, 2021
- Figure 17 Global Natural Killer (Nk) Cell Therapeutics Market: By Therapeutics, 2022-2029 (Usd Million)
- Figure 18 Global Natural Killer (Nk) Cell Therapeutics Market: By Therapeutics, Cagr (2022-2029)
- Figure 19 Global Natural Killer (Nk) Cell Therapeutics Market: By Therapeutics, Lifeline Curve
- Figure 20 Global Natural Killer (Nk) Cell Therapeutics Market: By Approaches, 2021
- Figure 21 Global Natural Killer (Nk) Cell Therapeutics Market: By Approaches, 2022-2029 (Usd Million)
- Figure 22 Global Natural Killer (Nk) Cell Therapeutics Market: By Approaches, Cagr (2022-2029)
- Figure 23 Global Natural Killer (Nk) Cell Therapeutics Market: By Approaches, Lifeline Curve
- Figure 24 Global Natural Killer (Nk) Cell Therapeutics Market: By Application, 2020
- Figure 25 Global Natural Killer (Nk) Cell Therapeutics Market: By Application, 2022-2029 (Usd Million)
- Figure 26 Global Natural Killer (Nk) Cell Therapeutics Market: By Application, Cagr (2022-2029)
- Figure 27 Global Natural Killer (Nk) Cell Therapeutics Market: By Application, Lifeline Curve
- Figure 28 Global Natural Killer (Nk) Cell Therapeutics Market: By End User, 2021
- Figure 29 Global Natural Killer (Nk) Cell Therapeutics Market: By End User, 2022-2029 (Usd Million)
- Figure 30 Global Natural Killer (Nk) Cell Therapeutics Market: By End User, Cagr (2022-2029)
- Figure 31 Global Natural Killer (Nk) Cell Therapeutics Market: By End User, Lifeline Curve
- Figure 32 Global Natural Killer (Nk) Cell Therapeutics Market: By Distribution Channel, 2021
- Figure 33 Global Natural Killer (Nk) Cell Therapeutics Market: By Distribution Channel, 2022-2029 (Usd Million)
- Figure 34 Global Natural Killer (Nk) Cell Therapeutics Market: By Distribution Channel, Cagr (2022-2029)
- Figure 35 Global Natural Killer (Nk) Cell Therapeutics Market: By Distribution Channel, Lifeline Curve
- Figure 36 Global Natural Killer (Nk) Cell Therapeutics Market: Snapshot (2021)
- Figure 37 Global Natural Killer (Nk) Cell Therapeutics Market: By Region (2021)
- Figure 38 Global Natural Killer (Nk) Cell Therapeutics Market: By Region (2022 & 2029)
- Figure 39 Global Natural Killer (Nk) Cell Therapeutics Market: By Region (2021 & 2029)
- Figure 40 Global Natural Killer (Nk) Cell Therapeutics Market: By Therapeutics (2022-2029)
- Figure 41 North America Natural Killer (Nk) Cell Therapeutics Market: Snapshot (2021)
- Figure 42 North America Natural Killer (Nk) Cell Therapeutics Market: By Country (2021)
- Figure 43 North America Natural Killer (Nk) Cell Therapeutics Market: By Country (2022 & 2029)
- Figure 44 North America Natural Killer (Nk) Cell Therapeutics Market: By Country (2021 & 2029)
- Figure 45 North America Natural Killer (Nk) Cell Therapeutics Market: By Therapeutics (2022-2029)
- Figure 46 Europe Natural Killer (Nk) Cell Therapeutics Market: Snapshot (2021)
- Figure 47 Europe Natural Killer (Nk) Cell Therapeutics Market: By Country (2021)
- Figure 48 Europe Natural Killer (Nk) Cell Therapeutics Market: By Country (2022 & 2029)
- Figure 49 Europe Natural Killer (Nk) Cell Therapeutics Market: By Country (2021 & 2029)
- Figure 50 Europe Natural Killer (Nk) Cell Therapeutics Market: By Therapeutics (2022-2029)
- Figure 51 Asia-pacific Natural Killer (Nk) Cell Therapeutics Market: Snapshot (2021)
- Figure 52 Asia-pacific Natural Killer (Nk) Cell Therapeutics Market: By Country (2021)
- Figure 53 Asia-pacific Natural Killer (Nk) Cell Therapeutics Market: By Country (2022 & 2029)
- Figure 54 Asia-pacific Natural Killer (Nk) Cell Therapeutics Market: By Country (2021 & 2029)
- Figure 55 Asia-pacific Natural Killer (Nk) Cell Therapeutics Market: By Therapeutics (2022-2029)
- Figure 56 South America Natural Killer (Nk) Cell Therapeutics Market: Snapshot (2021)
- Figure 57 South America Natural Killer (Nk) Cell Therapeutics Market: By Country (2021)
- Figure 58 South America Natural Killer (Nk) Cell Therapeutics Market: By Country (2022 & 2029)
- Figure 59 South America Natural Killer (Nk) Cell Therapeutics Market: By Country (2021 & 2029)
- Figure 60 South America Natural Killer (Nk) Cell Therapeutics Market: By Therapeutics (2022-2029)
- Figure 61 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: Snapshot (2021)
- Figure 62 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Country (2021)
- Figure 63 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Country (2022 & 2029)
- Figure 64 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Country (2021 & 2029)
- Figure 65 Middle East & Africa Natural Killer (Nk) Cell Therapeutics Market: By Therapeutics (2022-2029)
- Figure 66 Global Natural Killer (Nk) Cell Therapeutics Market: Company Share 2021 (%)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
